Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma

Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma

The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients.

This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).

Inclusion Criteria:

1. Prior Informed Consent Form
2. At least one measurable tumor, according to RECIST version 1.1.
3. Age > 20 years.
4. ECOG performance status 0 or 1.
5. Life expectancy > 3 months.
6. Confirmed Diagnosis of HCC
7. Adequate renal function (Serum creatinine ≦ 1.5 x upper limit of normal).

Exclusion Criteria:

1. Age <20 years old
2. Pregnancy
3. Contraindication for MRI: claustrophobia or MR non-compatible devices
4. Contraindication for MR contrast medium: severe adverse reaction or impaired renal function (Cre > 2.0)
5. History of other malignancy